Active, not recruitingPhase 2NCT03307980
Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- PF-06838435 (formerly SPK-9001)(biological)
- Enrollment
- 21 enrolled
- Eligibility
- 18-65 years · MALE
- Timeline
- 2017 – 2029
Study locations (25)
- UC Davis Comprehensive Cancer Center, Sacramento, California, United States
- UC Davis Ellison Ambulatory Care Clinic, Sacramento, California, United States
- UC Davis Medical Center department of Radiology, Sacramento, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- UC Davis Midtown Cancer Center, Sacramento, California, United States
- UC DavisHealth Main Hospital, Sacramento, California, United States
- LA Center for Bleeding and Clotting Disorders - Metairie, Metairie, Louisiana, United States
- Tulane Lakeside Hospital, Metairie, Louisiana, United States
- LA Center for Bleeding and Clotting Disorders, New Orleans, Louisiana, United States
- Tulane University Clinical Translational Unit, New Orleans, Louisiana, United States
- Tulane University Hospitals and Clinic, New Orleans, Louisiana, United States
- Tulane University School of Medicine, New Orleans, Louisiana, United States
- University Medical Center New Orleans, New Orleans, Louisiana, United States
- Louisiana Center for Advanced Medicine, Slidell, Louisiana, United States
- Mississippi Center for Advanced Medicine, Madison, Mississippi, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03307980 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.